Trial Profile
The Rationale of the Study is to Demonstrate That Degarelix Given at Three-Month Dosing Intervals Will Produce and Maintain Androgen Deprivation in Prostate Cancer Patients Through Immediate and Prolonged Testosterone Suppression, and to Provide Confirmatory Evidence of the Safety of Degarelix
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 23 Aug 2008 New trial record.